Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension

Cardiovascular Research

Volumn 63, Issue 1, 2004, Pages 176-185

  Roncal, C ^a   Orbe, J ^a   Rodriguez, J A ^a   Belzunce, M ^a   Beloqui, O ^b   Diez, J ^a   Paramo J A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Angiotensin II; Arterial hypertension; Atherosclerosis; Endothelium; PAI 1; Polymorphism

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CELL EXTRACT; LOSARTAN; MESSENGER RNA; PROTEIN DERIVATIVE;

ALLELE; ARTICLE; CELL CULTURE; CELL STIMULATION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HYPERTENSION; INCUBATION TIME; INTERMETHOD COMPARISON; LASER MICROSCOPY; PRIORITY JOURNAL; PROTEIN DETERMINATION; STATISTICAL SIGNIFICANCE; SUPERNATANT; UPREGULATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; FIBRINOLYSIS; GENETIC MARKERS; GENOTYPE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; STIMULATION, CHEMICAL;

EID: 2942544396     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.03.023     Document Type: Article

References (47)

1. Brasier A.R., Recinos A. III, Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vasc. Biol. 22:2002;1257-1266
2. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52:2000;11-34
3. Vaughan D.E. Angiotensin and vascular fibrinolytic balance. Am. J. Hypertens. 15:2002;3S-8S
4. Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., Vaughan D.E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 87:1993;1969-1973
5. Vaughan D.E., Lazos S.A., Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. 95:1995;995-1001
6. Nishimura H., Tsuji H., Masuda H., et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost. 77:1997;1189-1195
7. Podor T.J., Peterson C.B., Lawrence D.A., et al. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J. Biol. Chem. 275:2000;19788-19794
8. Paramo J.A., Colucci M., Collen D., van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br. Med. J. 291:1985;573-574
9. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2:1987;3-9
10. Eitzman D.T., Westrick R.J., Xu Z., Tyson J., Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 96:2000;4212-4215
11. Orbe J., Chorda C., Montes R., Paramo J.A. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha. Haematologica. 84:1999;306-311
12. Perez-Ruiz A., Montes R., Velasco F., et al. Regulation by nitric oxide of endotoxin-induced tissue factor and plasminogen activator inhibitor-1 in endothelial cells. Thromb. Haemost. 88:2002;1060-1065
13. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268:1993;10739-10745
14. Eriksson P., Kallin B., van't Hooft F.M., Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1851-1855
15. van der Bom J.G., Bots M.L., Haverkate F., Kluft C., Grobbee D.E. The 4G/5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood. 101:2003;1841-1844
16. Grenett H.E., Benza R.L., Fless G.M., Li X.N., Davis G.C., Booyse F.M. Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18:1998;1803-1809
17. Nakamura S., Nakamura I., Ma L., Vaughan D.E., Fogo A.B. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 58:2000;251-259
18. Chen H.C., Bouchie J.L., Perez A.S., et al. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler. Thromb. Vasc. Biol. 20:2000;2297-2302
19. Oubina M.P., de Las Heras N., Vazquez-Perez S., et al. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J. Hypertens. 20:2002;303-310
20. Ma L.J., Nakamura S., Whitsitt J.S., Marcantoni C., Davidson J.M., Fogo A.B. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int. 58:2000;2425-2436
21. Grancha S., Estelles A., Tormo G., et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb. Haemost. 81:1999;516-521
22. Castello R., Estelles A., Vazquez C., et al. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin. Chem. 48:2002;1288-1295
23. Paramo J.A., Alfaro M.J., Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor-relationship to deep vein thrombosis and influence of prophylaxis. Thromb. Haemost. 54:1985;713-716
24. Chavakis T., Pixley R.A., Isordia-Salas I., Colman R.W., Preissner K.T. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J. Biol. Chem. 277:2002;32677-32682
25. Festa A., D'Agostino R. Jr., Rich S.S., Jenny N.S., Tracy R.P., Haffner S.M. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation. 107:2003;2422-2427
26. Srikumar N., Brown N.J., Hopkins P.N., et al. PAI-1 in human hypertension: relation to hypertensive groups. Am. J. Hypertens. 15:2002;683-690
27. Carmeliet P., Moons L., Lijnen R., et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 96:1997;3180-3191
28. Peng L., Bhatia N., Parker A.C., Zhu Y., Fay W.P. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler. Thromb. Vasc. Biol. 22:2002;934-939
29. Motojima M., Ando T., Yoshioka T. Sp1-like activity mediates angiotensin-II-induced plasminogen-activator inhibitor type-1 (PAI-1) gene expression in mesangial cells. Biochem. J. 349:2000;435-441
30. Kobayashi N., Nakano S., Mita S., et al. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J. Pharmacol. Exp. Ther. 301:2002;459-466
31. Brown N.J., Murphey L.J., Srikumar N., Koschachuhanan N., Williams G.H., Vaughan D.E. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler. Thromb. Vasc. Biol. 21:2001;1071-1077
32. Yoshizumi M., Tsuji H., Nishimura H., et al. Atrial natriuretic peptide inhibits the expression of tissue factor and plasminogen activator inhibitor 1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb. Haemost. 79:1998;631-634
33. Yoshida M., Naito Y., Urano T., Takada A., Takada Y. L-158, 809 and (D-Ala(7))-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells. Thromb. Res. 105:2002;531-536
34. Peiretti F., Alessi M.C., Henry M., Anfosso F., Juhan-Vague I., Nalbone G. Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level. Arterioscler. Thromb. Vasc. Biol. 17:1997;1550-1560
35. Masutomo K., Makino N., Fushiki M.S. Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters. Mol. Cell. Biochem. 224:2001;19-27
36. Papakonstantinou E., Roth M., Kokkas B., Papadopoulos C., Karakiulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 38:2001;715-728
37. Konstantinides S., Schafer K., Thinnes T., Loskutoff D.J. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 103:2001;576-583
38. Eitzman D.T., Westrick R.J., Nabel E.G., Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. 95:2000;577-580
39. Sobel B.E., Taatjes D.J., Schneider D.J. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23:2003;1979-1989
40. Brown N.J., Abbas A., Byrne D., Schoenhard J.A., Vaughan D.E. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation. 105:2002;304-309
41. Brown N.J., Kumar S., Painter C.A., Vaughan D.E. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 40:2002;859-865
42. Vaughan D.E., Rouleau J.L., Ridker P.M., Arnold J.M., Menapace F.J., Pfeffer M.A. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation. 96:1997;442-447
43. Brown N.J., Agirbasli M., Vaughan D.E. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 34:1999;285-290
44. Fogari R., Mugellini A., Zoppi A., et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am. J. Hypertens. 15:2002;316-320
45. Diamantopoulos E.J., Andreadis E.A., Vassilopoulos C.V., et al. Increased plasma plasminogen activator inhibitor-1 levels: a possible marker of hypertensive target organ damage. Clin. Exp. Hypertens. 25:2003;1-9
46. Jeng J.R. Association of PAI-1 gene promoter 4G/5G polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension. Am. J. Hypertens. 16:2003;290-296
47. Hoffstedt J., Andersson I.L., Persson L., Isaksson B., Arner P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia. 45:2002;584-587